Luncheon Symposium: HER2-Targeted Antibody-Drug Conjugates in Metastatic Bladder Cancer: A New Era of Precision Oncology

Friday, October 31, 2025

12:00 - 12:45 GMT+0

This symposium is supported by B2B Presenting Sponsor Daiichi-Sankyo | AstraZeneca.

Chair(s)

Karima Oualla

Associate Professor of Medical Oncology
Hassan II University Hospital, Morocco

At the end of this session, attendees should be able to:

Understand the biology of HER2 alterations in urothelial carcinoma
Recall the mechanism of action, design and applications of ADCs in metastatic bladder cancer
Recognize the role of HER2 as a therapeutic target in urothelial carcinoma
Analyze the current and emerging clinical data on HER2-targeted ADCs

12:00 - 12:05 GMT+0

Welcome and Introductions
Chair: Karima Oualla – Hassan II University Hospital
12:05 - 12:15 GMT+0

The role of ERBB2 as an oncogene in bladder cancer
Speaker: Daniele Raggi – The Royal Marsden Foundation Trust
12:15 - 12:25 GMT+0

Targeting HER2 in Bladder Cancer Treatment
Speaker: Viktor Gruenwald – University Hospital Essen
12:25 - 12:40 GMT+0

Panel Discussion
Moderator: Karima Oualla – Hassan II University Hospital
Panelist: Kilian Martin Gust – Austria
Panelist: Daniele Raggi – The Royal Marsden Foundation Trust